Non-alcoholic fatty liver disease in the metabolic syndrome

Guiseppe Palasciano, Antonio Moschetta, Vincenzo O. Palmieri, Ignazio Grattagliano, Gianluca Iacobellis, Piero Portincasa

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

Original languageEnglish (US)
Pages (from-to)2193-2198
Number of pages6
JournalCurrent Pharmaceutical Design
Volume13
Issue number21
DOIs
StatePublished - Jul 2007

Fingerprint

Fatty Liver
Hyperlipidemias
Liver Cirrhosis
Lipid Peroxidation
Life Style
Liver Diseases
Oxidative Stress
Obesity
Hypertension
Non-alcoholic Fatty Liver Disease
Therapeutics

Keywords

  • Breath test
  • Metabolic syndrome
  • Non-alcoholic fatty liver disease
  • Non-alcoholic steatohepatitis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Palasciano, G., Moschetta, A., Palmieri, V. O., Grattagliano, I., Iacobellis, G., & Portincasa, P. (2007). Non-alcoholic fatty liver disease in the metabolic syndrome. Current Pharmaceutical Design, 13(21), 2193-2198. https://doi.org/10.2174/138161207781039652

Non-alcoholic fatty liver disease in the metabolic syndrome. / Palasciano, Guiseppe; Moschetta, Antonio; Palmieri, Vincenzo O.; Grattagliano, Ignazio; Iacobellis, Gianluca; Portincasa, Piero.

In: Current Pharmaceutical Design, Vol. 13, No. 21, 07.2007, p. 2193-2198.

Research output: Contribution to journalArticle

Palasciano, G, Moschetta, A, Palmieri, VO, Grattagliano, I, Iacobellis, G & Portincasa, P 2007, 'Non-alcoholic fatty liver disease in the metabolic syndrome', Current Pharmaceutical Design, vol. 13, no. 21, pp. 2193-2198. https://doi.org/10.2174/138161207781039652
Palasciano G, Moschetta A, Palmieri VO, Grattagliano I, Iacobellis G, Portincasa P. Non-alcoholic fatty liver disease in the metabolic syndrome. Current Pharmaceutical Design. 2007 Jul;13(21):2193-2198. https://doi.org/10.2174/138161207781039652
Palasciano, Guiseppe ; Moschetta, Antonio ; Palmieri, Vincenzo O. ; Grattagliano, Ignazio ; Iacobellis, Gianluca ; Portincasa, Piero. / Non-alcoholic fatty liver disease in the metabolic syndrome. In: Current Pharmaceutical Design. 2007 ; Vol. 13, No. 21. pp. 2193-2198.
@article{f5e127509d4148a398905e0f49f0e29a,
title = "Non-alcoholic fatty liver disease in the metabolic syndrome",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.",
keywords = "Breath test, Metabolic syndrome, Non-alcoholic fatty liver disease, Non-alcoholic steatohepatitis",
author = "Guiseppe Palasciano and Antonio Moschetta and Palmieri, {Vincenzo O.} and Ignazio Grattagliano and Gianluca Iacobellis and Piero Portincasa",
year = "2007",
month = "7",
doi = "10.2174/138161207781039652",
language = "English (US)",
volume = "13",
pages = "2193--2198",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Non-alcoholic fatty liver disease in the metabolic syndrome

AU - Palasciano, Guiseppe

AU - Moschetta, Antonio

AU - Palmieri, Vincenzo O.

AU - Grattagliano, Ignazio

AU - Iacobellis, Gianluca

AU - Portincasa, Piero

PY - 2007/7

Y1 - 2007/7

N2 - Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

AB - Non-alcoholic fatty liver disease (NAFLD) is often associated with features of the metabolic syndrome, carrying an increased risk to develop non-alcoholic steatohepatitis (NASH), the inflammatory form of liver steatosis. Epidemiological data confirm that obesity, diabetes, hypertension and hyperlipidemia are frequently found in NAFLD and worsen its prognosis because of increased risk of fibrotic evolution, eventually leading to liver cirrhosis. Recent studies confirm the close relationship between the metabolic syndrome and liver steatosis, and further support the detrimental role of oxidative stress and lipid peroxidation, which are pathophysiological processes present in both conditions. Novel diagnostic tools and life style modifications together with targeted therapeutic actions are urgently needed for the management of liver dysfunction in course of metabolic syndrome.

KW - Breath test

KW - Metabolic syndrome

KW - Non-alcoholic fatty liver disease

KW - Non-alcoholic steatohepatitis

UR - http://www.scopus.com/inward/record.url?scp=34447529333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447529333&partnerID=8YFLogxK

U2 - 10.2174/138161207781039652

DO - 10.2174/138161207781039652

M3 - Article

C2 - 17627552

AN - SCOPUS:34447529333

VL - 13

SP - 2193

EP - 2198

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -